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Background:  Alaska  Native  (AN)  children  have  experienced  high  rates  of invasive  pneumococcal  disease
(IPD).  In March  2010,  PCV13  was  introduced  statewide  in  Alaska.  We  evaluated  the  impact  of  PCV13  on
IPD in  children  and  adults,  45 months  after  introduction.
Methods:  Pneumococcal  sterile  site  isolates,  reported  through  state-wide  surveillance,  were  serotyped
using  standard  methods.  We  deﬁned  a pre-PCV13  time  period  2005–2008  and  post-PCV13  time  period
April  2010–December  2013; excluding  Jan  2009–March  2010  because  PCV13  was  introduced  pre-
licensure  in one  high-risk  region  in  2009.
Results:  Among  Alaska  children  <5 years,  PCV13  serotypes  comprised  65% of IPD in the  pre-PCV13  period
and  26%  in  the  PCV13  period.  Among  all  Alaska  children  <5  years,  IPD  rates  decreased  from  60.9 (pre)  to
25.4  (post)  per  100,000/year  (P<0.001);  PCV13  serotype  IPD decreased  from  37.7 to 6.4 (P<0.001).  Among
AN  children  <5 years,  IPD rates  decreased  from  149.2  to  60.8  (P<0.001);  PCV13  serotype  IPD  decreased
from  87.0  to  17.4  (P<0.001);  non-PCV13  serotype  IPD  did  not  change  signiﬁcantly.  Among  persons  5–17
and  ≥45  years,  the post-vaccine  IPD  rate  was  similar  to  the  baseline  period,  but  declined  in persons  18–44
years  (39%,  P < 0.001);  this  decline  was  similar  in AN  and  non-AN  persons  (38%,  P = 0.016,  43%,  P = 0.014,
respectively).
Conclusions:  Forty-ﬁve  months  after  PCV13  introduction,  overall  IPD and  PCV13-serotype  IPD  rates  had
decreased  58%  and  83%,  respectively,  in  Alaska  children  <5  years  of  age  when  compared  with  2005–2008.
We  observed  evidence  of indirect  effect  among  adults  with a 39%  reduction  in IPD  among  persons  18–44
years.
Published  by  Elsevier  Ltd.  This is  an  open  access  article  under  the CC  BY license  (http://The ﬁndings and conclusions in this report are those of the
uthors and do not necessarily represent the ofﬁcial position of
he Centers for Disease Control and Prevention.
. Background
Streptococcus pneumoniae remains a leading cause of disease
nd death worldwide. In the U.S., it is the most frequent bacterial
ause of meningitis, community-acquired pneumonia, acute otitis
edia and sinusitis [1]. Infections of otherwise sterile sites, which
re known as invasive pneumococcal disease (IPD), are routinely
eported to public health authorities in the US. [2]. Licensure of
∗ Corresponding author. Tel.: +1 907 729 3416; fax: +1 907 729 3429.
E-mail address: zwa8@cdc.gov (M.G. Bruce)
ttp://dx.doi.org/10.1016/j.vaccine.2015.07.080
264-410X/Published by Elsevier Ltd. This is an open access article under the CC BY licencreativecommons.org/licenses/by/4.0/).
the 7-valent pneumococcal conjugate vaccine (PCV7) in 2000 for
routine use in children <5 years and subsequent use of the vaccine
led to the near-elimination of vaccine type IPD among vaccinated
children and non-vaccinated persons through indirect effects [1,3].
In 2010, a vaccine with six additional serotypes, PCV13, was rec-
ommended to replace PCV7 [4]; the additional serotypes in PCV13
accounted for approximately 70% of the remaining burden of IPD
in US children <5 years [3,5,6].
Alaska Native people (AN) have historically suffered from an
excess burden of IPD compared with the overall US population
[7–9]. In the pre-vaccine era, AN children <2 years old had the
greatest disparity; the annualized IPD rate (450 per 100,000) was
among the highest in the world and 3.5 times higher than for non-
AN children of the same age [9]. After introduction of PCV7 in
2001, we  observed dramatic decreases in vaccine-type IPD (>95%)
and nasopharyngeal colonization (>90%) among AN children [6].
se (http://creativecommons.org/licenses/by/4.0/).
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owever, beginning in 2004, we saw a signiﬁcant trend of increas-
ng IPD rates due to non-vaccine serotypes, especially serotype 19A
10]. By 2007, non-vaccine IPD had more than doubled in AN chil-
ren <5 years. Overall IPD rates among AN children <5 years were
6% below the pre-vaccine baseline during 2001–2004; however,
y 2005–2007, the improvement over baseline rates was  only 37%
11]. While the introduction of PCV7 was an overall success, the
ncreases in non-vaccine type IPD and remaining burden of disease
ighlighted the need for other prevention measures.
In April 2010, PCV13 replaced PCV7 for widespread use in
laska. To evaluate the impact of PCV13, we describe the epidemi-
logy of IPD before and after PCV13 introduction using Alaska’s
opulation-based laboratory surveillance system. We  also describe
neumococcal nasopharyngeal colonization before and after PCV13
ntroduction using annual surveys of urban children <5 years old
nd residents of all ages living in eight rural AN villages [12–15].
hese data provide an early indication of the population-level effec-
iveness of PCV13 on IPD and pneumococcal colonization in a
igh-risk population where PCV7 has been used for over 10 years.
. Methods
As of 2010, the state of Alaska had a total population of 710,231,
0% (139,724) of whom are Alaska Native people; for less than 5
ear olds, a total population of 53,996, 28% (15,113) of whom are
laska Native (http://laborstats.alaska.gov/pop/popest.htm). Since
986, cases of IPD (deﬁned as isolation of S. pneumoniae from a nor-
ally sterile site in an Alaska resident) are reported from clinical
aboratories throughout Alaska to the CDC’s Arctic Investigations
rogram (AIP) in Anchorage. Isolates are sent to AIP where iden-
iﬁcation, and capsular serotyping are performed using standard
ethods. Urban regions of the state were deﬁned as the Anchorage
unicipality, Fairbanks North Star Borough, Juneau City and Bor-
ugh, and the Matanuska-Susitna Borough census areas. All other
egions were considered rural.
.1. Invasive isolates lab methods
Bacterial isolates. Pneumococci were conﬁrmed by colony mor-
hology, susceptibility to ethylhydroxycupreine hydrochloride
Optochin; Difco, Detroit), and bile solubility. All isolates were
erotyped by slide agglutination and conﬁrmed by the Quellung
eaction using group- and type-speciﬁc antisera (Statens Serum
nstitut, Copenhagen, Denmark).
.2. Carriage study lab methods
Nasopharyngeal swabbing and isolation of pneumococci. For each
tudy participant, a dacron swab was inserted through the naris
nto the nasopharynx and was immediately inoculated into skim
ilk, tryptone soy broth, glycerol, and glucose (STGG) transport
edium (2008–2013). Samples from the swabs were processed to
dentify and serotype pneumococci as previously described [16].
or study years 2008–2010, all isolates were serotyped by slide
gglutination and conﬁrmed by the Quellung reaction. Beginning
n study year 2011, we used a combined microbiologic, multiplex-
CR and serologic algorithm to serotype the pneumococcal isolates
17].
. Vaccine uptakeWe  evaluated the proportion of AN children age 19–35 months
ho received three or more doses of PCV between September 30,
003 and December 31, 2013 using electronic health records from
ribal health facilities. We  also accessed the National Immunization3 (2015) 4813–4819
Survey [18] public use ﬁles for 2013 to obtain the rate for 4+ doses of
PCV reported by race/ethnicity for 19–35 month old Alaskans who
were identiﬁed as “American Indian or Alaska Native only, non-
Hispanic” and for the overall Alaskan and US population of this age
group.
4. Statistical methods
The pre-PCV13 vaccine (baseline) period was deﬁned as 2005
through 2008 and was  compared to the period from April 2010
through December 2013. From January 2009 through March 2010
PCV13 was  used in very limited quantities (372 persons vaccinated)
in one region in a prelicensure open-label clinical trial [19]; this
period of partial introduction is excluded from comparisons. Pro-
portions were compared with a chi-squared or Fisher’s exact test
as appropriate. Changes in outcomes of pneumococcal carriage sur-
veys conducted between 2008 and 2013 were evaluated using the
Cochran–Armitage test of trend. All comparisons are two-sided. P
less than 0.05 is considered statistically signiﬁcant.
Data on IPD came from routine public health surveillance in
Alaska. The carriage study was  approved by the Centers for Dis-
ease Control and Prevention (CDC) and Alaska Area Institutional
Review Boards; written informed consent for participation was
obtained.
5. Results
5.1. Vaccine coverage
Using tribal facility electronic immunization records, 95–96% of
AN children 19–35 months of age had received 3+ doses of PCV in
2010-2011, which is consistent with the rate (96.8 ± 4.5%) reported
in the 2010 National Immunization Survey for Alaskans classiﬁed
as American Indian or Alaska Native only. Eighty-ﬁve percent of
AN children 19–35 months had received four doses of PCV during
2013, compared with 82% reported for US children in 2013 using the
National Immunization Survey [18]. Data from the 2010 National
Immunization Survey in Alaska shows 3+ PCV vaccine coverage of
86% for children (19–35 months of age) residing in urban Alaska
and 92% among children residing in rural Alaska.
5.2. Invasive pneumococcal disease rates
From 2005 to 2013, a total of 1198 IPD cases (all ages) were
reported in Alaska; the annual IPD rate for the pre-PCV13 vac-
cine time period of 2005–2008 (baseline) was  20.4 cases per
100,000 persons (minimum = 18.5, maximum = 22.2/100,000 per
year). The IPD rate in children <2 years old at baseline was
103.1/100,000 overall; 270.8 for AN children and 39.7 in non-AN
children. Compared to the baseline period, post introduction of
PCV13 (April 2010–December 2013), there was a 62% (P < 0.001)
and 61% (P = 0.013) decrease in IPD rates among AN and non-AN
children <2 years, respectively. (Table 1) Among <5 year olds, there
was a 59% decrease in the overall rate of IPD among AN and non-
AN children, (P < 0.001 and P = 0.002, respectively) (Table 1). Among
persons 5–17 and ≥45 years, the post-vaccine IPD rate was  similar
to the baseline period, but declined in persons 18–44 years (39%,
P < 0.001); this decline was similar in AN and non-AN persons (38%,
P = 0.016, 43%, P = 0.014, respectively).
5.3. Change in rates for PCV13 and non-PCV13 serotype IPD5.3.1. PCV13-serotype IPD rates
Changes in IPD rates were mainly due to decreases in PCV13
serotypes. During the baseline period, 58 of 82 (71%) IPD cases
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Table  1
Annual ratesa of invasive S. pneumoniae disease by time period, age group, race and vaccine serotype, Alaska 2005–2013.
Alaska Natives Non-Alaska Native Total
Age group 2005–2008 4/2010–2013 P-value 2005–2008 4/2010–2013 P-value 2005–2008 4/2010–2013 P-value
(years) Rate (number) Rate (number) Rate (number) Rate (number) Rate (number) Rate (number)
PCV13
<2 174.7 (40) 30.2 (7) <0.001 29.7 (18) 5.2 (3) 0.001 69.5 (58) 12.3 (10) <0.001
2–4 26.9 (9) 8.7 (3) 0.083 12.2 (11) 0 (0) <0.001 16.2 (20) 2.4 (3) <0.001
5–17  5.7 (8) 2.3 (3) 0.175 2.0 (8) 1.9 (7) 0.923 2.9 (16) 2.0 (10) 0.333
18–44  8.4 (17) 3.0 (6) 0.025 3.1 (27) 1.7 (14) 0.060 4.1 (44) 1.9 (20) 0.004
≥45  26.0 (34) 18.8 (27) 0.214 10.4 (80) 6.8 (57) 0.014 12.7 (114) 8.6 (84) 0.006
Total  20.4 (108) 8.6 (46) <0.001 6.6 (144) 3.7 (81) <0.001 9.3 (252) 4.7 (127) <0.001
<5  87.0 (49) 17.4 (10) <0.001 19.2 (29) 2.0 (3) <0.001 37.7 (78) 6.4 (13) <0.001
18+  15.4 (51) 9.7 (33) 0.037 6.5 (107) 4.2 (71) 0.005 8.0 (158) 5.2 (104) <0.001
Non-PCV13
<2  78.6 (18) 73.3 (17) 0.837 9.9 (6) 10.4 (6) 0.942 28.8 (24) 28.3 (23) 0.959
2–4  32.9 (11) 17.5 (6) 0.215 7.8 (7) 9.0 (8) 0.788 14.6 (18) 11.3 (14) 0.487
5–17  5.7 (8) 6.0 (8) 0.905 1.0 (4) 1.4 (5) 0.667 2.2 (12) 2.6 (13) 0.704
18–44  22.9 (46) 16.2 (32) 0.133 2.5 (22) 1.4 (12) 0.115 6.3 (68) 4.3 (44) 0.039
≥45  61.1 (80) 57.2 (82) 0.673 8.8 (68) 13.7 (115) 0.004 16.4 (148) 20.1 (197) 0.066
Total  30.7 (163) 27.2 (145) 0.290 4.9 (107) 6.7 (146) 0.014 9.9 (270) 10.7 (291) 0.376
<5  51.5 (29) 39.9 (23) 0.365 8.6 (13) 9.5 (14) 0.803 20.3 (42) 18.1 (37) 0.609
18+  37.9 (126) 33.4 (114) 0.326 5.5 (90) 7.6 (127) 0.018 10.9 (216) 12.0 (241) 0.344
Unknown
<2  17.5 (4) 0 (0) 0.061 0 (0) 0 (0) – 4.8 (4) 0 (0) 0.066
2–4  6.0 (2) 5.8 (2) 0.978 0 (0) 0 (0) – 1.6 (2) 1.6 (2) 1.0
5–17  0.7 (1) 0.8 (1) 0.970 0.3 (1) 0 (0) 0.520 0.4 (2) 0.2 (1) 0.668
18–44  2.0 (4) 1.5 (3) 0.743 0.5 (4) 0.4 (3) 0.768 0.8 (8) 0.6 (6) 0.657
≥45  3.8 (5) 7.0 (10) 0.280 2.0 (15) 1.7 (14) 0.681 2.2 (20) 2.4 (24) 0.756
Total  3.0 (16) 3.0 (16) 0.991 0.9 (20) 0.8 (17) 0.629 1.3 (36) 1.2 (33) 0.720
<5  10.7 (6) 3.5 (2) 0.170 0 (0) 0 (0) – 2.9 (6) 1.0 (2) 0.184
18+  2.7 (9) 3.8 (13) 0.441 1.2 (19) 1.0 (17) 0.699 1.4 (28) 1.5 (30) 0.856
All  cases
<2 270.8 (62) 103.4 (24) <0.001 39.7 (24) 15.5 (9) 0.013 103.1 (86) 40.7 (33) <0.001
2–4 65.9 (22) 32.0 (11) 0.048 20.0 (18) 9.0 (8) 0.056 32.4 (40) 15.4 (19) 0.006
5–17  12.0 (17) 9.0 (12) 0.453 3.2 (13) 3.2 (12) 1.0 5.5 (30) 4.8 (24) 0.592
18–44  33.3 (67) 20.7 (41) 0.016 6.1 (53) 3.5 (29) 0.014 11.2 (120) 6.8 (70) <0.001
≥45  90.9 (119) 83.0 (119) 0.482 21.2 (163) 22.2 (186) 0.667 31.3 (282) 31.1 (305) 0.921
Total  54.1 (287) 38.9 (207) <0.001 12.4 (271) 11.1 (244) 0.239 20.5 (558) 16.6 (451) <0.001
<5  149.2 (84) 60.8 (35) <0.001 27.9 (42) 11.6 (17) 0.002 60.9 (126) 25.4 (52) <0.001
18+  56.0 (186) 46.9 (160) 0.099 13.2 (216) 12.9 (215) 0.803 20.4 (402) 18.6 (375) 0.209
a Rates per 100,000 persons per year
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on children <2 years were due to a PCV13 serotype; proportions
ere similar for AN persons, 40 of 58 (69%) and 18 of 24 for
on-AN persons (75%). Post PCV13 introduction, IPD rates due to
CV13 serotypes declined by 82% (69.5–12.3/100,000, P < 0.001)
n children <2 years; the decline in AN children and non-AN
hildren <2 years was 83% (174.7–30.2/100,000, P = 0.001) and
3% (29.7–5.2/100,000, P = 0.001), respectively. PCV13 IPD rates
mong children 2–4 years declined by 85% (16.2–2.4/100,000,
 < 0.001); among non-AN children 2–4 years, rates declined by
00% (12.2–0.0/100,000, P < 0.001). A signiﬁcant decline in PCV13
PD rates was observed among adults age 18 years and older
Table 1, P < 0.001).
Overall IPD rates among both rural and urban children <5 years
eclined 62% (119.7–46.1/100,000, P < 0.001) and 54% (36.8–17.1,
 < 0.001), respectively, from the pre- to post-vaccine periods.
ates of PCV13 IPD among both rural and urban children <5
ears declined 81% (73.1–13.7, P < 0.001) and 85% (23.2–3.42,
 < 0.001), respectively, from the pre- to post-vaccine periods.
mong rural AN <5 years, declines in IPD rates (219.5–83.6,
 < 0.001, −62%) and PCV13 IPD (73.1–13.7, P < 0.001 −81%) were
bserved. Among urban AN <5 years of age, overall IPD rates
57.4–34.0, P = 0.224, −41%) and PCV13 IPD rates (28.7–7.54, = 0.086 −74%) were statistically unchanged; however, among
rban non-AN <5 years, signiﬁcant declines in IPD rates (32.7–13.4,
 = 0.002, −59%) and PCV13 IPD (22.1–2.51, P < 0.001 −89%) were
bserved.5.4. Non-PCV13-serotype IPD rates
Post-PCV13 introduction, IPD rates due to non-PCV13 serotypes
demonstrated no statistically signiﬁcant changes in children ≤17
years or adults ≥45 years, (16.4–20.1/100,000, P = 0.066, Table 1).
5.5. IPD by individual serotype
In all age groups, IPD rates in the post-PCV13 vaccine period
showed statistically signiﬁcant declines in PCV13 serotypes, 6A, 7F
and 19A (P ≤ 0.002, Table 2); for non-PCV13 serotypes, the only sig-
niﬁcant decline was  observed for 12F (P < 0.001) (due to a regional
12F outbreak during the baseline period) [20]. A signiﬁcant increase
was observed for 23A (P = 0.009). Among children <5 years old with
PCV13-type disease, we  observed statistically signiﬁcant decreases
in serotypes 3 (P = 0.040), 7F and 19A (P < 0.001 for both). No sig-
niﬁcant changes in rates of non-PCV13 serotype IPD were observed
in children <5 years old (Table 2). The most common non-vaccine
serotypes among adults ≥45 years in the post vaccine period were
22F, 16F, 23A, 6C, 8 and 9N.
5.6. Clinical presentation, disease severity and mortalityFor children <5 years old, IPD hospitalization rates decreased
46% from 35.8 to 19.5 (P = 0.002) and pneumonia rates decreased
57% from 34.3 to 14.7 (P < 0.001) from the pre- to post-vaccine
4816 M.G. Bruce et al. / Vaccine 33 (2015) 4813–4819
Table 2
Rates of IPD by serotype, time period and age group, Alaska, 2005–2013.
Serotype 2005–2008 4/2010–2013 % Change P-value
N Rate per 100,000 N Rate per 100,000
All ages
PCV13, not PCV7 1 5 0.2 1 0.04 −80 0.125
3  30 1.1 34 1.3 13 0.620
5  1 0.04 0 0 −100 0.500
6A  12 0.4 1 0.04 −92 0.002
7F  92 3.4 54 2.0 −41 0.002
19A  89 3.3 29 1.1 −67 <0.001
PCV7  4 7 0.3 2 0.07 −71 0.109
6B  2 0.07 0 0 −100 0.250
9V  4 0.2 0 0 −100 0.063
14  4 0.2 1 0.04 −75 0.219
18C  2 0.07 0 0 −100 0.250
19F  3 0.1 5 0.2 67 0.508
23F  1 0.04 0 0 −100 0.500
Other  serotypesa 6C 8 0.3 18 0.7 125 0.052
8b 34 1.3 23 0.8 −32 0.148
9Nb 7 0.3 15 0.6 114 0.093
10Ab 11 0.4 11 0.4 0 1.0
11Ab 7 0.3 11 0.4 57 0.359
12Fb 49 1.8 18 0.7 −63 <0.001
15A  15 0.6 17 0.6 13 0.728
15Bb 5 0.2 7 0.3 40 0.581
15C  4 0.2 6 0.2 50 0.549
16F  12 0.4 23 0.8 92 0.065
17Fb 6 0.2 5 0.2 −17 0.774
20b 19 0.7 15 0.6 −21 0.500
22Fb 28 1.0 37 1.4 32 0.268
23A  6 0.2 19 0.7 217 0.009
23B  9 0.3 8 0.3 −11 0.815
31  10 0.4 15 0.6 50 0.327
33Fb 11 0.4 12 0.4 9 0.839
35B  7 0.3 8 0.3 14 0.804
Other  known 22 0.8 23 0.8 5 0.883
Unknown  36 1.3 33 1.2 −8 0.720
Total  558 20.5 451 16.5 −19 <0.001
PCV5  (PCV13-PCV7-6A) 217 8.0 118 4.3 −46 <0.001
PCV6  (PCV13-PCV7) 229 8.4 119 4.4 −48 <0.001
PCV7  23 0.8 8 0.3 −65 0.007
<5  Years of age
PCV13, not PCV7 1 0 0 0 0 –
3  7 3.4 1 0.5 −86 0.040
5  0 0 0 0 –
6A  3 1.5 0 0 −100 0.127
7F  25 12.1 2 1.0 −92 <0.001
19A  40 19.3 8 3.9 −80 <0.001
PCV7  4 0 0 0 0 –
6B  0 0 0 0 –
9V  1 0.5 0 0 −100 0.503
14  0 0 0 0 –
18C  0 0 0 0 –
19F  1 0.5 2 1.0 102 0.619
23F  1 0.5 0 0 −100 0.503
Other  serotypes 6C 2 1.0 0 0 −100 0.253
8b 1 0.5 0 0 −100 0.503
9Nb 2 1.0 0 0 −100 0.253
10Ab 2 1.0 2 1.0 1 0.992
11Ab 1 0.5 1 0.5 1 0.995
12Fb 6 2.9 4 2.0 −33 0.560
15A  3 1.5 4 2.0 35 0.716
15Bb 1 0.5 4 2.0 304 0.215
15C  1 0.5 3 1.5 203 0.370
16F  2 1.0 2 1.0 1 0.992
17Fb 1 0.5 0 0 −100 0.503
20b 0 0 0 0 –
22Fb 5 2.4 4 2.0 −19 0.766
23A  0 0 1 0.5 NA 0.497
23B  5 2.4 1 0.5 −80 0.128
31  0 0 1 0.5 NA 0.497
33Fb 4 1.9 3 1.5 −24 0.737
35B  2 1.0 3 1.5 52 0.253
Other  known 4 1.9 4 2.0 1 0.988
Unknown  6 2.9 2 1.0 −66 0.184
Total  126 60.9 52 25.4 −58 <0.001
PCV5  (PCV13-PCV7-6A) 72 34.8 11 5.4 −85 <0.001
PCV6  (PCV13-PCV7) 75 36.2 11 5.4 −85 <0.001
PCV7  3 1.5 2 1.0 −33 0.696
a Other serotypes with N ≥ 10 the two periods
b Serotypes in PPV23 but not PCV13
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eriods. No statistically signiﬁcant changes in the proportion of
hildren <5 years with meningitis, pneumonia, or empyema were
bserved; however, the proportion hospitalized increased from
9% (74/126) to 77% (40/51, P = 0.021). For persons of all ages,
PD hospitalization rates remained unchanged 16.6–14.7 (P = 0.069)
nd pneumonia rates decreased 19% from 15.1 to 12.3 (P = 0.006)
rom the pre- to post-vaccine periods. No statistically signiﬁcant
hanges in the proportion of persons (all ages) with meningitis,
neumonia, or empyema were observed between the two  time
eriods; however, the proportion of persons with IPD hospitalized
ose from 81% (452/557) to 89% (399/448, P = 0.001). For per-
ons of all ages, IPD mortality rates demonstrated no statistically
igniﬁcant changes (1.8–2.2, P = 0.294); however, the proportion
f persons with IPD who died rose from 8.8% (49/558) to 13.4%
60/447) between the two time periods (P = 0.019). Among children
5 years, IPD mortality rates demonstrated no statistically signif-
cant changes (0.97–1.95, P = 0.446); the proportion of children <5
ears with IPD who died also demonstrated no statistically signif-
cant change 1.6% (2/126) to 7.7% (4/52, P = 0.061). Two  deaths in
he 4-year baseline period were serotypes 19A and 35F and the four
eaths during the 45-month post vaccine period were serotypes
5F, 16F, and 12F (n = 2).
. Colonization
We  obtained 15,533 nasopharyngeal swabs from 2008 to 2013
mong children <5 in Anchorage and among children (all ages) and
dults from eight rural Alaska villages. During 2008–2013, 36% of
hildren swabbed were colonized with S. pneumoniae in Anchor-
ge; 15% of adults and 67% of children from the rural villages were
olonized. The proportion of children colonized with S. pneumo-
iae remained stable throughout the study period and adults ≥18
ears showed a signiﬁcant rise from 15% in 2008 to 19% in 2013.
n all ages, carriage of PCV13-type S. pneumoniae decreased and
on-PCV13-type carriage increased from 2008 to 2013 (P < 0.0001).
ost PCV13 introduction, the proportion of Anchorage children
5 years old colonized by a PCV13 serotype declined from 25%
o 7% (P < 0.0001) [all-sampled denominator data shown in brac-
ets, 9–3% (P < 0.0001)] and for those colonized with a non-PCV13
erotype, the proportion rose from 70% to 91% [25–35% (P = 0.001)].
mong rural children colonized by a PCV13 serotype, the propor-
ion declined from 26% to 3% (P < 0.0001) [18–2% (P < 0.0001] and
or those colonized with a non-PCV13 serotype, the proportion
ose from 68% to 92% (P < 0.0001) [47–65% (P < 0.0001)]. Among
ural adults ≥18 years colonized with a PCV13 serotype, the pro-
ortion declined from 24% to 9% (P < 0.0001) [4–2% (P = 0.0002)]
nd for those colonized with a non-PCV13 serotype, the propor-
ion rose from 65% to 80% (P < 0.0001) [10–15% (P < 0.0001)] [16].
mong adults ≥45 years old, carriage of non-PCV13 serotypes
ncreased from 63% to 81% (P < 0.05) [7–10% (P = 0.01)] and for
CV13 serotypes decreased from 26% to 11% (P < 0.05) [3–1%
P = 0.03)] from 2008 to 2013.
. Conclusions
PCV13 introduction into Alaska’s childhood immunization
chedule in 2010 resulted in a greater than 50% reduction in IPD
nd near elimination of PCV13 type disease among children <5
ears. Among <2 year olds, vaccine-type disease rates decreased
y 83% with decreases in vaccine-type disease shown in both
N and non-AN children; however, in the post vaccine period,
ates of vaccine-type disease among AN children <2 years remain
igher than non-AN children at 30.2 and 5.2 cases per 100,000,
espectively. These declines in overall IPD and vaccine-type dis-
ase rates post PCV13 are consistent with data from recent studies3 (2015) 4813–4819 4817
among Navajo children [21], children living in Australia [22], the
US [23–25], the UK [26,27], Denmark [28], Spain [29] and Thailand
[30]. If the effects of PCV13 are similar to PCV7 [6], we expect to
see further declines in rates of vaccine-type disease among AN and
non-AN children over the next 3–4 years. Forty-ﬁve months after
the introduction of PCV13 vaccine in Alaska, we see no evidence of
serotype replacement among IPD cases in children <5 years old.
IPD rates declined sharply in both urban and rural Alaska chil-
dren from the pre- to post-vaccine period. However, despite higher
vaccine coverage among rural Alaska children, overall IPD rates
among rural children <5 years remain three times those of urban
children; rates of PCV13 IPD among rural children are four times
those of urban children in the post-vaccine period. The higher rates
of IPD observed among rural Alaska children (most of whom are AN)
are likely related to factors such as increased household crowding,
low socio-economic status, high unemployment and lack of access
to piped water.
We  observed evidence of indirect effect among adults with a
39% reduction in IPD among persons 18–44 years and a 36% reduc-
tion in PCV13 IPD rates among adults age 18 years and older
(data not shown). This is likely due to the effect of introduction
of PCV13 vaccine and not due to the effect of 23-valent pneu-
mococcal polysaccharide vaccine (PPV23) use in Alaskan adults. A
review of rates of adult IPD caused by non-PCV13 PPV23 serotypes
demonstrates no statistically signiﬁcant change from the pre- to
post-vaccine period. A recent study of the impact of PCV13 on
IPD in Spain demonstrated reductions in IPD (from a pre- to a
post-vaccine period) of 34% in persons 5–64 years and reductions
of 47% in PCV5-type disease (1, 3, 5, 6A, 7F, 19A) [29]. Simi-
lar reductions in incidence of IPD and vaccine-type disease in
adults have been documented in recent studies from Denmark,
the UK and the Southwestern US among the Navajo [21,27,28].
Further observation is warranted to determine if this trend con-
tinues.
Post-PCV13 vaccine, we observed statistically signiﬁcant
declines in IPD (all ages) for PCV13 serotypes 6A (−92%), 7F (−41%),
and 19A (−67%); in all other PCV13 serotypes there were no signif-
icant changes. No statistically signiﬁcant declines were observed
for non-PCV13 serotypes except for 12F (due to a regional 12F out-
break in baseline period). A recent study done by Moore et al. also
showed large reductions in IPD among children for serotypes 19A
(−85%) and 7F (−94%) with no statistically signiﬁcant reduction in
serotype 3 disease [23]. Many of the recent studies looking at PCV13
impact on IPD have demonstrated signiﬁcant declines in serotypes
7F and 19A post vaccine introduction [25,29].
This study found signiﬁcant decreases in rates of IPD hospital-
ization and pneumonia diagnosis among children <5 years (pre- to
post-PCV13 period). Among all ages, signiﬁcant decreases in rates of
pneumonia diagnosis (pre- to post-PCV13 period) were noted. No
signiﬁcant change (pre- to post-PCV13 period) in the proportion
of persons with meningitis, pneumonia or empyema were noted;
however, this study did ﬁnd signiﬁcant increases in the proportion
who were hospitalized or died. A study of IPD after the implemen-
tation of PCV13 in Massachusetts by Iroh Tam et al. reported similar
ﬁndings in regards to clinical presentation; however, described no
signiﬁcant change in hospitalization rates and no change in mortal-
ity from pre- to post-PCV13 [24]. A study by Guevarra et al. in Spain
found decreases in the proportion of persons with pneumonia,
complicated pneumonia and bacteremia from pre- to post-PCV13
[29]. Harboe et al. noted statistically signiﬁcant declines in mor-
tality in Danish adolescents and adults from pre- to post-PCV13. It
may  be too early in Alaska to determine the full effects of PCV13 on
hospitalization and mortality.
We found little change in the overall proportion of persons col-
onized among both children and adults from pre- to post-PCV13;
however, noted sharp decreases in colonization with PCV13-type
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neumococci among Alaska children and adults after introduction
f PCV13 in Alaska. Recent studies by van Hoek et al. in the UK
nd Dagan et al. in Israel show that the odds of carrying PCV13
erotypes was markedly reduced after use of the PCV13 vaccine in
hose countries [31,32].
Study limitations include a likely underestimation of IPD rates
ue to incomplete case ascertainment, the possibility of changes
n blood culture practices over the study period, the fact that
mall numbers for some subgroup comparisons may  have limited
ur power to detect differences, and that colonization data comes
rom nine locations in Alaska and may  not be generalizable to all
laskans. Finally, not all changes in IPD, carriage, and serotype dis-
ribution can be attributed solely to PCV13; however, the dramatic
ecreases in PCV13-type IPD and carriage are likely due to the vac-
ine.
In less than 4 years since introduction of the PCV13 vaccine in
laska, we have observed overall declines in IPD in children and
dults and have seen substantial reductions of PCV13-type inva-
ive disease and carriage in both groups which supports continued
se of this vaccine in Alaska. However, despite the fact that IPD
ates among AN children <2 years have declined by 62% since intro-
uction of PCV13, these rates are still six times higher than the
ates seen in non-AN children of the same age. To date, no evidence
f serotype replacement has been observed in this population of
hildren, but there does appear to be some serotype replacement
ccurring among adults which merits further observation.
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